Advertisement

Anti-Idiotype Monoclonal Antibodies as LPS Internal Images and Immunologic Protection Against Endotoxin Lethality in Mice

  • S. K. Field
  • M. Pollack
  • D. C. Morrison

Abstract

Gram negative bacterial infections continue to be a major cause of morbidity and mortality both in the United States and throughout the world (Anon). The existing evidence would strongly support the concept that, in many cases of Gram negative bacteremia and sepsis, endotoxic lipopolysaccharides (LPS) released from the microbial outer cell membrane are a major contributing factor to the pathophysiology of disease. In this respect, while LPS is generally regarded not to be directly toxic to host cells and tissues, it is potentially capable of stimulating cells to release a variety of inflammatory mediators, including tumor necrosis factor (TNF), many of the interleukins (Il-1, Il-6, Il-8, Il-10), products of phospholipid metabolism such as prostaglandins, leukotrienes and platelet activating factor (PAF) and procoagulant activity in the form of tissue factor (Morrison and Ryan, 1979). These biologically active mediators serve to promote a more generalized and often uncontrolled systemic inflammatory response which results in the hypotension, disseminated intra-vascular coagulation and multisystem organ failure characteristic of endotoxin shock.

Keywords

Affinity Column Coupling Buffer Eikenella Corrodens Immunologic Protection Mouse Myeloma Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Braude, A.I. and Douglas. H. Passive immunization against the local Shwartzman reaction, J. Inmmnal. 108: 505–512 (1972).Google Scholar
  2. Cross, A.S. and Opal. S. Therapeutic intervention in sepsis with antibody to endotoxin: is there a future?, 1. Endotoxin Research. 1: 57–69 (1994).Google Scholar
  3. Field, S., Pollack. M. and Morrison. D.C. Development of an anti-idiotype monoclonal antibody mimicking the structure of lipopolysaccharide (LPS) inner-core determinants, Microb. Pathog. 15: 103–120 (1993).PubMedCrossRefGoogle Scholar
  4. Field, S.K. and Morrison. D.C. A hamster anti-idiotype monoclonal antibody. mimicking the inner-core region of Gram-negative bacterial lipopolysaccharide (LPS), stimulates LPS inner-core-specific serum antibodies in hamsters. J. Endotoxin Research 1: 120–130 (1994).Google Scholar
  5. Field. S.K. and Morrison, D.C. An anti-idiotype antibody which mimics the inner-core region of lipopolysaccharide protects mice against a lethal challenge with endotoxin, Infect. Immun. 62: 3994–3999 (1994).PubMedGoogle Scholar
  6. Greenman, R., Schein. R.M.H., Martin, M.A., Wenzel, R.P., MacNtyre, N.R., Emmanuel, G., Herman, C., Kohler, R.B., McCarthy, M., Plouffe, J. Russel, J.A. and the XOMA Study Group. A controlled clinical trial of E5 murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients,, LAMA 266: 1097–1102 (1991).CrossRefGoogle Scholar
  7. Increase in national hospital discharge survey rates for septicemia-United States, 1979–1987. MMWR 39: 31–34 (1990).Google Scholar
  8. Jacobs, D.M. and Morrison, D.C. Stimulation of a T-independent primary anti-hapten response in vino by TNP-lipopolysaccharide,,1. I»imunol. 114: 360–366 (1975).Google Scholar
  9. Kato, T., Takazoe, I. and Okuda. K. Protection of mice against the lethal toxicity of a lipopolysaccharide (LPS) by immunization with anti-idiotype antibody to a monoclonal antibody to lipid A from Eikenella corroders LPS, Infect. Immun. 58: 416–420 (1990).PubMedGoogle Scholar
  10. McCabe. W.R. and Greely. A. Immunization with R mutants of S. minnesota. I. Protection against challenge with heterologous Gram-negative bacilli, J. Innnunol. 108: 601–610 (1972).Google Scholar
  11. McNamara, M.K., Ward. R.E. and Kohler, H. Monoclonal idiotype vaccine against Streptococcus pneumoniae infection, Science 226: 1325–1326 (1984).PubMedCrossRefGoogle Scholar
  12. Monafo, W.J., Greenspan. N.S., Cebra-Thomas, J. and Davie. J.M. Modulation of the murine response to streptococcal group A carbohydrate by immunization with monoclonal anti-idiotype„1. Imnncnol. 139: 2702–2707 (1987).Google Scholar
  13. Morrison. D.C. and Ryan. J.L. A review: bacterial endotoxins and host immune function, Achy. hmminol. 28: 293–430 (1979).Google Scholar
  14. Shreiber, J.R., Nixon, K.L., Tosi. M.F., Pier, G.B. and Patawaran. M.B. Anti-idiotype-induced, lipopolysaccharide-specific antibody response to pseudomonas aeru;inosa. Il. Isotype and functional activity of the anti-idiotype-induced antibodies. J. Immunol. 146: 188–193 (1991).Google Scholar
  15. Stein, K.E. and Soderstrom, T. Neonatal administration of idiotype or anti-idiotype primes for protection against E. coli K13 infection in mice. 1. Eap. Med. 166: 1001–1011 (1984).Google Scholar
  16. Su, S., McNamara, W., Apicella, M.A. and Ward, R.E. A nontoxic, idiotype vaccine against gram-negative bacterial infections, J. Immunol. 148: 234–238 (1992).PubMedGoogle Scholar
  17. Westerink, M.A., Giardina, P. Campagnari, J.A. and Apicella. M.A. The thymus-dependent nature of the murine antibody response to a monoclonal anti-idiotypic antibody to the Neisseria menin;itidis serogroup C capsular polysaccharide, Microb. Pnthog. 8: 411–419 (1990).CrossRefGoogle Scholar
  18. Ziegler, E.J., Fisher. C.J. Sprung, C.L., Straube, R.C., Sadoff, J.C. Foulke. J.C., Wortel. C.H., Fink, M.P., Dellinger, R.P., Teng. N.N.H., Allen. I.E., Berger, H.J., Knatterud, G. Lobuglio. A.F., Smith, C.R., and the HA-IA Study Group. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin, N. Engl.1. Med. 324: 429–436 (1991).CrossRefGoogle Scholar
  19. Ziegler, E.J. McCutchan, J.A., Fierer, A., Glauser. M.P., Sadoff, J.C. Douglas, H., and Braude, A.I. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Esclrerichia coli, N. Engl. J. Med. 307: 1225–1230 (1982).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • S. K. Field
    • 1
  • M. Pollack
    • 2
  • D. C. Morrison
    • 3
  1. 1.Department of Molecular BiologyBristol-Meyers Squibb Pharmaceutical Research InstitutePrincetonUSA
  2. 2.Department of MedicineUniformed Services University of the Health SciencesBethesdaUSA
  3. 3.Cancer CenterUniversity of Kansas Medical CenterKansas CityUSA

Personalised recommendations